Publications by authors named "Maria Pangerl"
Hepatol Commun
November 2024
Article Synopsis
- Immunotherapy combinations are the standard treatment for advanced hepatocellular carcinoma (HCC), with growing evidence supporting lenvatinib as a strong first-line option.
- A retrospective study analyzed 412 patients treated with either atezolizumab/bevacizumab (AZ/BV) or lenvatinib (LEN) across 18 European hospitals, revealing that those on AZ/BV experienced longer progression-free survival.
- Despite comparable survival rates between the two treatments overall, AZ/BV posed a higher risk of liver issues in patients with pre-existing liver function impairment, highlighting the need for careful patient monitoring.
Article Synopsis
- Lenvatinib is effective as a first-line treatment for advanced hepatocellular carcinoma (HCC) in a real-world setting, with a median overall survival of 12.8 months in a cohort from Germany and Austria.
- Patients who met specific inclusion criteria from the REFLECT study experienced better survival rates compared to those who did not meet these criteria.
- Factors such as impaired liver function, poor performance status, macrovascular invasion, and high AFP levels were identified as independent negative prognostic indicators impacting patient outcomes.
